283 related articles for article (PubMed ID: 33724703)
1. Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade.
Buchbinder EI; Weirather JL; Manos M; Quattrochi BJ; Sholl LM; Brennick RC; Bowling P; Bailey N; Magarace L; Ott PA; Haq R; Izar B; Giobbie-Hurder A; Hodi FS
Cancer Med; 2021 Apr; 10(8):2627-2635. PubMed ID: 33724703
[TBL] [Abstract][Full Text] [Related]
2. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Hintzsche JD; Gorden NT; Amato CM; Kim J; Wuensch KE; Robinson SE; Applegate AJ; Couts KL; Medina TM; Wells KR; Wisell JA; McCarter MD; Box NF; Shellman YG; Gonzalez RC; Lewis KD; Tentler JJ; Tan AC; Robinson WA
Melanoma Res; 2017 Jun; 27(3):189-199. PubMed ID: 28296713
[TBL] [Abstract][Full Text] [Related]
3. The mutational landscape of mucosal melanoma.
Nassar KW; Tan AC
Semin Cancer Biol; 2020 Apr; 61():139-148. PubMed ID: 31655118
[TBL] [Abstract][Full Text] [Related]
4. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.
Cosgarea I; Ugurel S; Sucker A; Livingstone E; Zimmer L; Ziemer M; Utikal J; Mohr P; Pfeiffer C; Pföhler C; Hillen U; Horn S; Schadendorf D; Griewank KG; Roesch A
Oncotarget; 2017 Jun; 8(25):40683-40692. PubMed ID: 28380455
[TBL] [Abstract][Full Text] [Related]
5. NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors.
Thielmann CM; Chorti E; Matull J; Murali R; Zaremba A; Lodde G; Jansen P; Richter L; Kretz J; Möller I; Sucker A; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Paschen A; Livingstone E; Zimmer L; Schadendorf D; Hadaschik E; Ugurel S; Griewank KG
Eur J Cancer; 2021 Dec; 159():113-124. PubMed ID: 34742158
[TBL] [Abstract][Full Text] [Related]
6. Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
Iida Y; Salomon MP; Hata K; Tran K; Ohe S; Griffiths CF; Hsu SC; Nelson N; Hoon DSB
BMC Cancer; 2018 Oct; 18(1):1054. PubMed ID: 30373548
[TBL] [Abstract][Full Text] [Related]
7. Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy.
Lee J; Chang JS; Roh MR; Jung M; Lee CK; Oh BH; Chung KY; Koom WS; Shin SJ
Cancer Res Treat; 2020 Jul; 52(3):730-738. PubMed ID: 32054150
[TBL] [Abstract][Full Text] [Related]
8. Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE).
Swami N; Hwang WL; Guo JA; Hoffman H; Abramowitz MC; Elbakouny Z; Beltran H; Chipidza F; Choueiri T; Pra AD; Huang F; Kaochar S; Kantoff P; Kim DW; Kishan AU; Kobetz E; Marinac C; Mucci LA; Muralidhar V; Pollack A; Sanford NN; Schaeffer EM; Spratt DE; Zhao SG; Rebbeck TR; Nguyen PL; Feng FY; Mahal BA; Alshalalfa M
Cancer Genet; 2021 Nov; 258-259():61-68. PubMed ID: 34551377
[TBL] [Abstract][Full Text] [Related]
9. Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.
Loo K; Smithy JW; Postow MA; Betof Warner A
Front Immunol; 2021; 12():810388. PubMed ID: 35087529
[TBL] [Abstract][Full Text] [Related]
10. Transient activation of tumoral DNA damage tolerance pathway coupled with immune checkpoint blockade exerts durable tumor regression in mouse melanoma.
Zhuo M; Gorgun FM; Tyler DS; Englander EW
Pigment Cell Melanoma Res; 2021 May; 34(3):605-617. PubMed ID: 33124186
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.
Zheng M
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101940
[TBL] [Abstract][Full Text] [Related]
13. Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors.
Li Y; Wang Q; Chen Y; Zhao L
Br J Cancer; 2022 Nov; 127(8):1411-1423. PubMed ID: 35871235
[TBL] [Abstract][Full Text] [Related]
14. H3K27me3 and EZH2 expression in melanoma: relevance for melanoma progression and response to immune checkpoint blockade.
Hoffmann F; Niebel D; Aymans P; Ferring-Schmitt S; Dietrich D; Landsberg J
Clin Epigenetics; 2020 Feb; 12(1):24. PubMed ID: 32041674
[TBL] [Abstract][Full Text] [Related]
15. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract][Full Text] [Related]
16. Biological Pathway-Derived TMB Robustly Predicts the Outcome of Immune Checkpoint Blockade Therapy.
Miao YR; Liu CJ; Hu H; Yang M; Guo AY
Cells; 2022 Sep; 11(18):. PubMed ID: 36139377
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
18. Mucosal melanoma: clinical, histological and c-kit gene mutational profile of 86 French cases.
Cinotti E; Chevallier J; Labeille B; Cambazard F; Thomas L; Balme B; Leccia MT; D'Incan M; Vercherin P; Douchet C; Rubegni P; Perrot JL
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1834-1840. PubMed ID: 28543798
[TBL] [Abstract][Full Text] [Related]
19. High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade.
Onieva JL; Xiao Q; Berciano-Guerrero MÁ; Laborda-Illanes A; de Andrea C; Chaves P; Piñeiro P; Garrido-Aranda A; Gallego E; Sojo B; Gálvez L; Chica-Parrado R; Prieto D; Pérez-Ruiz E; Farngren A; Lozano MJ; Álvarez M; Jiménez P; Sánchez-Muñoz A; Oliver J; Cobo M; Alba E; Barragán I
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012390
[TBL] [Abstract][Full Text] [Related]
20. Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy.
Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
Front Immunol; 2021; 12():657575. PubMed ID: 33936087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
